Skip to content
Review

REGIONAL CITRATE ANTICOAGULATION VERSUS NO ANTICOAGULATION DURING CONTINUOUS RENAL REPLACEMENT THERAPY IN PATIENTS WITH SEVERE LIVER FAILURE: A SYSTEMATIC REVIEW

Sep 2026 · BJN Abstract-CBN26 · 0 citations

Abstract

Introdução: The optimal anticoagulation strategy for continuous renal replacement therapy (CRRT) in patients with severe liver failure remains uncertain. Although regional citrate anticoagulation (RCA) may improve filter survival, concerns regarding citrate accumulation and metabolic complications have limited its use in this population. Objetivo: To evaluate the efficacy and safety of RCA versus NACG during CRRT. Método: We performed a systematic review according to PRISMA guidelines. PubMed, Embase, and Web of Science were searched through May 2026 for studies comparing RCA versus NACG during CRRT in adults with severe liver failure-associated acute kidney injury. Eligible randomized and observational studies reporting filter survival, mortality, bleeding, or metabolic complications were included. Resultados: Of 403 studies, 3 met the inclusion criteria (1 RCT [Bai, 2024], 1 case-control [Yu, 2020], and 1 retrospective cohort [Bhagat, 2026]), totaling 267 patients (RCA: n=106; NACG: n=161). Filter survival advantages favored RCA in two studies. In the RCT, RCA significantly decreased filter failure rates (27% vs. 56%) and extended filter duration (44 vs. 28 hours). The case-control study demonstrated a reduced risk of filter failure with RCA (HR = 0.46; 95% CI: 0.26–0.82), achieving a median filter lifespan >72 hours compared to 39.5h in the NACG group. Conversely, the cohort reported a shorter median time to filter clotting in the RCA group (47 vs. 54h). There were no significant differences in mortality or bleeding between strategies. In the RCT, 28-day mortality was 52% (RCA) vs. 49% (NACG), while the case-control study reported in-hospital mortality rates of 63.4% and 54.8%, respectively. Bleeding occurred in 0% vs. 4% of patients in the RCT and 5.1% vs. 4.3% of total circuits in the case-control study. Regarding metabolic safety, the RCT observed a higher incidence of biochemical citrate accumulation (total-to-ionized calcium ratio > 2.5: 57% vs. 7%) and hypocalcemia (82% vs. 51%) with RCA. The case-control study also noted accumulation signs exclusively in the RCA arm (4/79 vs. 0/162 filters). In contrast, the cohort reported completion acidosis rates of 23% with RCA vs. 29% with NACG, with no detected hypocalcemia. Conclusão: Available evidence suggests regional citrate anticoagulation may prolong filter lifespan during CRRT in patients with severe liver failure, without increasing mortality or bleeding risk. However, uncertainty remains regarding citrate-related metabolic complications.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.